IONIS PHARMACEUTICALS INC

Ionis secures first FDA‑approved therapy for Alexander disease with Zanvastro, while its cardio drug pelacarsen falls short—shaping investors’ view of its rare‑disease promise.

Ionis Pharmaceuticals projects $875‑$900M revenue in 2026, with TRYNGOLZA poised for $3B+ sales, while EPS stays negative but top‑line growth and EBITDA rise.

Ionis Pharma’s stock dips 40% amid Arrowhead’s breakthrough, yet analysts still favor its RNA‑based Tryngolza pipeline and long‑term prospects.

Ionis slashes Tryngolza price by 93% ahead of FDA approval, aiming to boost FCS and sHTG uptake and lift stock upside to $106.

Ionis Pharmaceuticals doubles Tryngolza sales forecast to $2 billion, positioning itself for robust 2026 growth amid a strong antisense oligonucleotide launch and strategic partnerships.

Ionis Pharmaceuticals Inc has made significant breakthroughs in biotechnology, including a 31% surge in stock value and positive Phase-III data for its drug Olezarsen, highlighting the company’s potential to revolutionize the treatment of severe blo…

Ionis Pharmaceuticals Inc. continues to demonstrate steady growth and promise, driven by positive developments in its RNA-targeted drug discovery and development, as well as analyst confidence and strategic endorsements.

Ionis Pharmaceuticals Inc. faces a mixed bag of financial news, with declining stock value and trading suspension, but also reaffirmed analyst confidence and a growing HDAC inhibitors market.

Ionis Pharmaceuticals Inc remains a leader in biotechnology, driven by innovative research and strategic partnerships, despite facing financial challenges.